Lynparza in combination with abiraterone granted priority review in US
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Read Moreby John Pinching | Aug 16, 2022 | News | 0
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Read Moreby Selina McKee | May 6, 2020 | News | 0
NHS England has expanded access to targeted hormone therapies for advanced prostate cancer
Read Moreby Selina McKee | Jun 6, 2018 | News | 0
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
Read Moreby Selina McKee | Jun 5, 2018 | News | 0
AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.
Read Moreby Selina McKee | Nov 21, 2017 | News | 0
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
